Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

Whatever the consensus opinion may be, our team at StockStory cuts through the noise by conducting independent analysis to determine a company’s long-term prospects. That said, here are three stocks facing legitimate challenges and some alternatives worth exploring instead.

BJ's (BJRI)

Consensus Price Target: $44 (2.5% implied return)

Founded in 1978 in California, BJ’s Restaurants (NASDAQ: BJRI) is a chain of restaurants whose menu features classic American dishes, often with a twist.

Why Do We Pass on BJRI?

1. Weak same-store sales trends over the past two years suggest there may be few opportunities in its core markets to open new restaurants
2. Challenging supply chain dynamics and bad unit economics are reflected in its low gross margin of 14.7%
3. ROIC of 3% reflects management’s challenges in identifying attractive investment opportunities

BJ’s stock price of $42.93 implies a valuation ratio of 18.5x forward P/E. To fully understand why you should be careful with BJRI, check out our full research report (it’s free).

C.H. Robinson Worldwide (CHRW)

Consensus Price Target: $193.36 (-2.6% implied return)

Engaging in contracts with tens of thousands of transportation companies, C.H. Robinson (NASDAQ: CHRW) offers freight transportation and logistics services.

Why Does CHRW Fall Short?

1. Sales tumbled by 4% annually over the last two years, showing market trends are working against its favor during this cycle
2. Competitive supply chain dynamics and steep production costs are reflected in its low gross margin of 7.4%
3. Diminishing returns on capital suggest its earlier profit pools are drying up

C.H. Robinson Worldwide is trading at $198.50 per share, or 32.1x forward P/E. Read our free research report to see why you should think twice about including CHRW in your portfolio.

Centene (CNC)

Consensus Price Target: $43.88 (2.8% implied return)

Serving nearly 1 in 15 Americans through its government healthcare programs, Centene (NYSE: CNC) is a healthcare company that manages government-sponsored health insurance programs like Medicaid and Medicare for low-income and complex-needs populations.

Why Does CNC Give Us Pause?

1. Underwhelming customer growth over the past two years shows the company faced challenges in winning new contracts
2. Incremental sales over the last five years were much less profitable as its earnings per share fell by 5.1% annually while its revenue grew
3. Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions

At $42.68 per share, Centene trades at 18x forward P/E. Dive into our free research report to see why there are better opportunities than CNC.

Stocks We Like More

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.